New collaboration in pursuit of personalised therapies for MND
The Perron Institute and Sydney-based neurosciences research organisation GenieUs Genomics have signed an agreement to pursue Antisense Oligonucleotide (AO) therapies for motor neurone disease (MND).
Starting with MND, GenieUs is currently mapping and sub categorising neurodegenerative diseases through deep phenotyping. The aim is to understand the commonalities and differences between individuals diagnosed with such disorders.
Professor Anthony Akkari (top left), head of MND research and Dr Loren Flynn (top right) postdoctoral researcher, both at the Perron Institute and Murdoch University, are working with GenieUs CEO Matt Keon and his team.
“The Perron Institute/Murdoch University expertise in disease-modifying AO therapeutics and the skill of GenieUs in genomic data science makes this a perfect combination,” Professor Akkari said.
“I’m very proud of the commitment by our Perron Institute team and GenieUs in partnering on a journey to find novel therapies for MND patients,” Professor Akkari said.
“This agreement capitalises on the already strong working relationship between our two organisations.”
GenieUs Co-Founder Matt Keon (bottom centre) is also excited about the potential of the agreement.
“Bringing together WA’s AO know-how and our organisation’s expertise in multi integrated genomic data creates an excellent platform to deliver highly specific precision medicine in a shorter time,” Mr Keon said.
“Our shared aim is to slow or stop the progression of neurodegenerative diseases such as MND.”
In welcoming the agreement, Perron Institute CEO Steve Arnott said the institute took enormous pride in its research scientists and clinicians for the recognition they were achieving in Australia and internationally.